Landfar Bio-medicine Stock Forum

Landfar Bio-medicine's high P/S ratio may not be justified due to its poor revenue performance. Investors expecting a turnaround may face disappointment if the P/S falls to levels in line with recent growth rates. Without significant improvement, it's hard to prevent the P/S ratio from declining to a more reasonable level.

Despite respectable revenue growth, the company's share price has significantly underperformed the market over the past five years. Last year's performance suggests unresolved challenges, worse than the annualised loss of 8% over the last half decade.

Despite Landfar Bio-medicine's falling price and revenues, its high P/S ratio suggests investor optimism. However, inconsistent revenue growth and expected industry growth of 825% may make these prices unsustainable. Without significant medium-term performance improvement, the P/S ratio may decline to a more reasonable level.